1. Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemia
- Author
-
Hagop M. Kantarjian, Kayleigh Marx, and Farhad Ravandi
- Subjects
Oncology ,medicine.medical_specialty ,Anthracycline ,Population ,Pharmacology ,Vosaroxin ,03 medical and health sciences ,chemistry.chemical_compound ,Myelogenous ,0302 clinical medicine ,Internal medicine ,medicine ,Pharmacology (medical) ,education ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,education.field_of_study ,biology ,business.industry ,Health Policy ,Topoisomerase ,Myeloid leukemia ,medicine.disease ,Leukemia ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Cytarabine ,business ,030215 immunology ,medicine.drug - Abstract
Introduction: A first-in-class anticancer quinolone derivative with topoisomerase II activity, mechanistically, vosaroxin is similar to the anthracycline class. However, vosaroxin displays advantageous pharmacokinetic properties such as minimal metabolism, a lack of free radical production, is not a substrate for the P glycoprotein efflux pump, and can exert its antineoplastic activity independently of P53 function. Vosaroxin has shown encouraging results when combined with cytarabine in older patients with relapsed or refractory acute myeloid leukemia (AML) while balancing early toxicity and mortality, making it a compelling novel therapy for acute myelogenous leukemia.Areas covered: Herein, we review the clinical data from published and internationally presented clinical trials utilizing vosaroxin for AML in the elderly, and relapsed and refractory population. Pivotal trials reviewed include the multicenter, phase II, REVEAL-1 study of single-agent vosaroxin in untreated elderly patients and the...
- Published
- 2016